Role of maintenance immunotherapy in metastatic urothelial carcinoma; which patients are eligible? | Satellite Symposium

Satellite Symposium Agenda:

Expert Talk 1: Front-line Management for Advanced Bladder Cancer: Chemo is No Longer Enough

Jorge A. Garcia

*Oncology University Hospitals Seidman Cancer Center, Cleveland, OH, USA. Expert Talk 2: Ongoing Clinical Trials in Advanced Urothelial Carcinoma and Future Directions

Vadim Koshkin

*Division of Hematology and Oncology, University of California San Francisco Expert Talk 3: Treatment Options for Second-Line Therapy and Beyond in Urothelial Carcinoma

Shilpa Gupta

*Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio Expert Panel Discussion and Questions & Answers

Panelists: Shilpa Gupta, Vadim Koshkin and Jorge A. Garcia

Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio, Division of Hematology and Oncology, University of California San Francisco and *Oncology University Hospitals Seidman Cancer Center, Cleveland, OH, USA.

Learning Objectives:

After completing the independent medical educational activity, learners will be able to:

1. Understand and explain relevant and current clinical trials and updates regarding immunotherapy as maintenance therapy in la/mUC patients.

2. Learn and understand which patients should be followed up with immunotherapy maintenance treatment.

Certificate of attendance: The certificates will be given to those attendees who will complete pre & post symposium evaluation quiz.

Conflict of interests: No known conflict of interests

Acknowledgment: This symposium is supported by an educational grant from Pfizer and Merck.